For research use only. Not for therapeutic Use.
Anselamimab(CAT: I040856) is a potent and selective monoclonal antibody targeting CD3, designed to modulate immune responses effectively. It is currently under investigation for its potential in treating autoimmune diseases and inflammatory conditions by regulating T-cell activation and reducing excessive immune reactions. With high specificity and efficacy, Anselamimab offers a promising therapeutic approach for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its advanced formulation ensures optimal bioavailability and stability, making it a valuable candidate in immunology research. Explore Anselamimab’s potential for groundbreaking advancements in inflammation and immunology research.
| CAS Number | 2414866-63-8 |
| Purity | ≥95% |
